Stock Evaluator: Nkarta, Inc. (NKTX)

Nkarta, Inc. NKTX

$1.25 0.04 3.31%
November 17, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,043,829
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Commentary & Analysis


Financial Summary

Share Statistics NKTX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $86.8 $202.9 21%
Shares Out (Mil) 74.6 55.4 56%
Institutional Ownership 99.5% 92.9% 89%
Float (Mil) 60.7 40.7 51%
Beta 1.25 1.04 73%
Avg Daily Volume (000s) 2,090 566 80%
Price Change
(52-week)
(35.6%) 41.0% 27%
Growth NKTX Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.2% na
Net Income (5yr) (2.6%) (10.3%) 37%
EPS (5yr) 23.7% 15.8% 74
Dividends (5yr) na 0.0% na
Cash Flow (5yr) (48.8%) (15.7%) 8%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 2 2 3
Current EPS ($0.455) ($1.825) ($1.513)
Month Ago EPS ($0.400) ($1.707) ($1.753)
# Rev Up 0 0 0
# Rev Down 1 0 0
Three Months Ago EPS ($0.400) ($1.707) ($1.753)
Year/Year Chg 1.8% 29.7% (17.9%)
Financials NKTX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $39 na
Net Income (TTM) (Mil) ($129) ($44) 9%
EPS (TTM) ($1.734) ($1.400) 16%
Operating Cash Flow (TTM) (Mil) ($100) ($34) 6%
Net Cash Flow (TTM) (Mil) ($12) ($1) 32%
Long-Term Debt (Q1) (Mil) $65 $4 41%
Enterprise Value (Q1) (Mil) $40 $144 15%
Valuation NKTX Industry
Median
Percentile
(All Stocks)
P/B 0.40 1.97 9%
P/E na 17.5 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.8 na
Ratios NKTX Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.6% na
Net Margin na (50.6%) na
ROA (35.1%) (47.4%) 15%
ROE (46.6%) (53.5%) 16%
Liabilities to Assets 30.1% 29.7% 21%
F-Score 1 3 1%

Nkarta, Inc. did not pass any screens on 11/16/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors